Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Restoring cancer's death sentence.

Anthony Letai1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Dana 530B, Boston, Massachusetts 02115, USA. anthony_letai@dfci.harvard.edu

Cancer Cell
|November 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

What does BCL-2 do? From new molecular insights to the clinical implications.

Cell death and differentiation·2026
Same author

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Cell death and differentiation·2025
Same author

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Blood advances·2025
Same author

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

bioRxiv : the preprint server for biology·2025
Same author

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockade.

bioRxiv : the preprint server for biology·2025
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
Same journal

From prediction to interpretation in computational pathology.

Cancer cell·2026
See all related articles

Resistance to the BCL-2 antagonist ABT-737 is determined by MCL-1 expression. Lowering MCL-1 levels enhances ABT-737 efficacy, offering a promising strategy for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The BCL-2 family of proteins regulates apoptosis.
  • ABT-737 is a novel antagonist targeting BCL-2, a key regulator of apoptosis.
  • Understanding resistance mechanisms to ABT-737 is crucial for its clinical application.

Discussion:

  • Expression of MCL-1, an antiapoptotic protein, is identified as a primary determinant of resistance to ABT-737.
  • Synergistic effects are observed when MCL-1 levels are reduced in conjunction with BCL-2 antagonism.
  • The findings provide insights into the molecular mechanisms underlying ABT-737's selective cancer cell killing.

Key Insights:

  • MCL-1 expression levels directly correlate with resistance to ABT-737.
  • Reducing MCL-1 is a viable strategy to overcome ABT-737 resistance.

Related Experiment Videos

  • The study highlights the importance of targeting specific antiapoptotic proteins in cancer therapy.

    • Outlook:

    • Developing clinical strategies to lower MCL-1 levels alongside BCL-2 antagonism.
    • Exploring the therapeutic potential of combining ABT-737 with MCL-1 inhibitors.
    • Advancing BCL-2 antagonism as a clinically relevant anticancer strategy.